The Brand Name COPRIME Has Generic Salt :: Trimethoprim 

COPRIME  Is From Company Concept Priced :: Rs. 14.47

COPRIME have Trimethoprim is comes under Sub class #N/A of  Main Class #N/A

Main Medicine Class:: #N/A  Sub Medicine Class :: #N/A 

Indications for Drugs ::

Urinary tract infections,Gastroenteritis,Pneumocystis jiroveci pneumonia,Resp tract infections

Drug Dose ::

Adult: PO Susceptible infections Acute infections: 100 or 200 mg twice daily. UTI 100 mg 12 hrly for 10 days. Pneumocystis jiroveci pneumonia W/ dapsone: 5 mg/kg 3 times/day for 21 days. Max: 20 mg/kg/day. IV Gastroenteritis; Resp tract infections; Treatment and prophylaxis of UTI 200 mg 12 hrly. Child: 6-8 mg/kg/day in 2 divided doses. Alternatively, 6 wk-5 mth: 25 mg bid, 6 mth-5 yr: 50 mg bid, 6-12 yr: 100 mg bid. Renal impairment: CrCl (ml/min) 15-27 Normal dose for 3 days, thereafter half the normal doses. <15 Half the normal dose from the start of the treatment. Contraindication ::

Hypersensitivity, serious haematological disorders, severe renal impairment, megaloblastic anaemia secondary to folate depletion.

Drug Precautions ::

Renal and hepatic impairment, porphyria, patients with potential folate deficiency, elderly, pregnancy, lactation, children with fragile X chromosome associated with mental retardation. Perform regular haematological examination.

Drug Side Effects ::

Nausea, vomiting, glossitis, pruritus, skin rash, fever, hyponatremia, hyperkalaemia, photosensitivity, liver enzyme elevation, , raised serum creatinine and BUN, blood dyscrasias, cholestatic jaundice, anaphylaxis, aseptic meningitis. Potentially Fatal: Stevens-Johnson syndrome, toxic epidermal necrolysis.

Pregnancy category ::

3

Drug Mode of Action ::  

Trimethoprim inhibits the conversion of bacterial dihydrofolic acid to tetrahydrofolic acid which is important for the synthesis of DNA. It may be bacteriostatic or bactericidal depending on growth conditions. It is active against a wide range of gm-ve and gm+ve aerobes, as well as some protozoa.

Drug Interactions ::

Concurrent use increased risk of blood dyscrasias with azathioprine, methotrexate, pyrimethamine; increased risk of hyperkalaemia with ACE inhibitors; increased risk of hyponatraemia when used with both potassium-sparing diuretics and thiazides; increased risk of bleeding with warfarin; increased risk of lithium toxicity; increased digoxin, phenytoin, procainamide, lamivudine, stavudine, repaglinide, rosiglitazone, dofetilide serum levels; decreased ciclosporin levels. Concurrent use with dapsone increased serum levels of both and increased risk of dapsone toxicity.